Design and Synthesis of the First-in-Class MC4R Antagonist, PF-07258669 with [4,5]-Spirocyclic Core

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2023; 19(08): 0830
DOI: 10.1055/s-0042-1752721

Innovative Drug Discovery and Development

Contributor(s):

Antonia F. Stepan (Roche)

,

Seong Heon Kim (Hyundai Pharm)

melanocortin-4-receptor antagonist - loss of appetite - clinical candidate - spirocycles - SBDD

Article published online:
14 July 2023

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany